RSS Feed

Latest news

New once-daily triple combination inhaler for COPD

New once-daily triple combination inhaler for COPD

Trelegy Ellipta is the second 3-in-1 treatment for...

New obesity treatment rejected by NICE

New obesity treatment rejected by NICE

The obesity treatment naltrexone/bupropion (Mysimba)...

New MIMS table helps GPs adjust antidiabetic doses in renal impairment

New MIMS table helps GPs adjust antidiabetic doses in renal impairment

Prescribers can now consult a handy MIMS table to check...

First NICE asthma guideline recommends oral treatment before LABA

First NICE asthma guideline recommends oral treatment before LABA

NICE suggests offering a leukotriene receptor antagonist...

Dupilumab: first biologic for moderate-to-severe atopic dermatitis

Dupilumab: first biologic for moderate-to-severe atopic dermatitis

Dupilumab (Dupixent) is the first biologic treatment...


New and deleted products

Promo Image

New Products

Products added to MIMS

Promo Image

Deleted Products

Products removed from MIMS


Most popular

Antidepressants, a Guide to Switching and Withdrawing

Instructions for changing or stopping antidepressants.

H.pylori: Eradication Regimens (NICE)

Summary of NICE guidance on Helicobacter treatment.

Hormone Replacement Therapy (HRT)

Hormone doses and costs of HRT preparations.

Syringe Driver Drug Compatibility

Compatibility of drugs mixed in a syringe driver.

Opioid Analgesics: Approximate Potency Equivalence with Oral Morphine

Guide to potencies of opioid analgesics, for dose conversion.


Featured MIMS resources

Promo Image

Routine childhood immunisation schedule

Quick-reference summary of the UK childhood vaccination programme.

Promo Image

Menopause: diagnosis and management

At-a-glance summary of the first NICE guideline on menopause.


Manufacturers

Manufacturers

Contact details and drug listings for manufacturers in MIMS


New products coming soon to MIMS

Check back soon to find MIMS listings for the following new drugs:

Brinavess (vernakalant)

Fertavid (follitropin beta)

Kyleena (levonorgestrel)

Panzyga (human normal immunoglobulin)

Suliqua (insulin glargine/lixisenatide)

Trelegy Ellipta (vilanterol/fluticasone/umeclidinium)

Vemlidy (tenofovir alafenamide fumarate)


Partner CPD from MIMS Learning

knowledge 1 Credit

Initiated, funded and reviewed by Almirall. Date of Preparation: July 2017; UKSOY3620d

WEBCAST 0.5 Credits

Initiated, funded and reviewed by TEVA UK. Date of Preparation: November 2017; UK/QV/17/0003

Webcast 0.5 Credits

This learning module has been initiated, funded and reviewed by Edwards Lifesciences.

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

This site is intended for healthcare professionals.